556,521 Shares in Roivant Sciences Ltd. $ROIV Bought by Tiff Advisory Services LLC

Tiff Advisory Services LLC bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 556,521 shares of the company’s stock, valued at approximately $6,272,000. Roivant Sciences makes up approximately 1.5% of Tiff Advisory Services LLC’s holdings, making the stock its 11th largest holding.

Other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. grew its stake in shares of Roivant Sciences by 3.8% during the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock worth $99,695,000 after acquiring an additional 365,468 shares during the last quarter. BlackBarn Capital Partners LP raised its position in shares of Roivant Sciences by 15.2% in the 1st quarter. BlackBarn Capital Partners LP now owns 4,750,000 shares of the company’s stock valued at $47,928,000 after purchasing an additional 625,000 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Roivant Sciences by 12.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock worth $50,787,000 after purchasing an additional 506,219 shares in the last quarter. Nuveen LLC purchased a new stake in Roivant Sciences during the 1st quarter worth approximately $31,988,000. Finally, Charles Schwab Investment Management Inc. grew its position in Roivant Sciences by 1.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,847,625 shares of the company’s stock worth $28,733,000 after purchasing an additional 35,123 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $20.56 on Friday. The company has a market capitalization of $14.04 billion, a PE ratio of -36.71 and a beta of 1.23. The company has a fifty day moving average of $16.85 and a 200 day moving average of $13.27. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $21.35.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 683,818 shares of the firm’s stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $14.95, for a total transaction of $10,223,079.10. Following the sale, the chief executive officer directly owned 1,969,767 shares of the company’s stock, valued at $29,448,016.65. This trade represents a 25.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Vivek Ramaswamy sold 1,195,000 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $12.50, for a total value of $14,937,500.00. Following the transaction, the insider owned 36,089,108 shares of the company’s stock, valued at approximately $451,113,850. This represents a 3.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,428,958 shares of company stock valued at $80,491,638 in the last quarter. Company insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ROIV. Guggenheim reaffirmed a “buy” rating and issued a $25.00 price target on shares of Roivant Sciences in a report on Friday. Citigroup upped their target price on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday. The Goldman Sachs Group lifted their price target on Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. JPMorgan Chase & Co. boosted their price target on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 18th. Finally, Bank of America raised their price objective on Roivant Sciences from $12.00 to $16.50 and gave the stock a “neutral” rating in a research note on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $22.56.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.